Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Secretin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Subcutaneous Secretin | DRUG | - |
Inclusion Criteria: 1. Able to give informed consent 2. DSM-IV diagnosis of schizophrenia 3. 18-55 years of age 4. Stable medication \> 4 weeks Exclusion Criteria: 1. Active suicidal ideation 2. Concurrent DSM-IV comorbidity with any substance dependence 3. A urine drug screen that is qualitative...
Secretin is an investigational small molecule being studied for the treatment of schizophrenia. It is being developed by Repligen Corporation (NASDAQ: RGEN). The drug is currently in Phase 2 clinical development, though no active trials are ongoing and the only completed trial has finished.
Secretin is a small molecule being studied for its effects on information processing in schizophrenia. The specific molecular target of Secretin is not disclosed in the available information. The drug is being evaluated for its potential to modulate cognitive processes in patients with schizophrenia.
Secretin is being developed by Repligen Corporation, a biopharmaceutical company traded on NASDAQ under the ticker symbol RGEN. The company is investigating the drug as a potential treatment for schizophrenia, and it is currently in Phase 2 clinical development.
Secretin is in Phase 2 clinical development for schizophrenia. It is an investigational drug, meaning it has not been approved by regulatory authorities. The only clinical trial for Secretin has been completed, and there are no active trials currently enrolling patients.
Secretin has been studied in one clinical trial, identified as NCT00235274, titled 'Effects of RG1068 (Secretin) on Information Processing in Schizophrenia'. This Phase 2 trial was completed in the United States and enrolled 30 participants with schizophrenia. The trial was randomized and double-blind, though it had an uncontrolled design.
Yes, Secretin is also known as RG1068. The clinical trial NCT00235274, which studied the drug's effects on information processing in schizophrenia, refers to the drug as RG1068. This alternative name is used in the trial title and is associated with the same investigational compound.